ClinicalTrials.gg

Program

donzakimig

Also written as “UCB1381” and “Donzakimig”.

Its studies are mostly in Dermatitis, Atopic, led by UCB.

Furthest: phase 2, since Mar 3, 20222 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB20 open or runningphase 2since Mar 3, 2022Mar 3, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2022First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05277571 · 109 enrolled · United States
  2. Nov 29, 2024Phase 1 study in Healthy ParticipantsNCT06716879 · 32 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06716879Healthy Participants · United States1CompletedApr 4, 202532
NCT05277571Dermatitis, Atopic · United States2CompletedJul 17, 2025109

How it is read

Names in the registry

  • “UCB1381”, 1 entry
  • “Donzakimig”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.